Description

Retatrutide is Eli Lilly’s investigational peptide that acts as a triple agonist stimulation of GLP‑1, GIP, and glucagon receptors. It’s designed for profound appetite suppression, improved glycemic control, increased energy expenditure, and notable fat and weight loss—phase 2 trials reported mean weight loss of ~24.2% over 48 weeks with higher doses (~12 mg) Axios+15New England Journal of Medicine+15Peptide Research+15.

📦 Formulation & Reconstitution

• Presentation: 10 mg powder in a pen or vial (e.g. “10 mg pen”)

• Mixing instructions (per peptide research protocols): Reconstitute with 1 mL sterile cold water to yield a 10 mg/mL solution—100 units = 10 mg

• Store at room temperature as powder; once reconstituted, keep refrigerated at 2–8 °C and inject from chilled solution .

💉 Dosing & Titration Guide

Standard protocol (based on phase 2 GLP-1‑GIP‑Glucagon tri‑agonist trials):

• Start at 1–2 mg once weekly, escalating every 4 weeks: 2 → 4 → 8 → 12 mg as tolerated. Maximum dose in trials: 12 mg weekly Peptide Research+11NiceRx+11Reddit+11

• Lower starting doses (0.5–1 mg) may be safer for unscreened individuals or those with prior adverse reactions Reddit

Alternative micro‑dosing method (for 10 mg vial/pen):

• 10 units = 1 mg, 20 units = 2 mg, 100 units = 10 mg

• Example: weekly injection of 20 units (2 mg), increasing by 10 units per dose as tolerated, max ~150 units (15 mg per week maximum) Peptide Research+1Peptide Research+1

• Delivered via SC injection into abdomen or upper thigh, rotated sites weekly pep-pedia.org+1NiceRx+1.

⚙️ Efficacy & Clinical Outcomes

• Phase 2 data: at 12 mg weekly, up to 24.2% mean body weight reduction over 48 weeks. Women and those with BMI ≥ 35 saw greatest effects Axios+11New England Journal of Medicine+11Reddit+11

• Meta-analyses show significantly greater weight loss at doses ≥ 4 mg vs placebo, with improvements in waist circumference, blood pressure, lipids, glycemic control PMC+1New England Journal of Medicine+1

• Secondary benefits: reductions in liver fat, triglycerides (up to ~40%), apoC-III (~38%) and return from prediabetes to normoglycemia in many patients Verywell Health+2Reuters+2New England Journal of Medicine+2

⚠️ Side Effects & Safety Profile

• Most common side effects were gastrointestinal: nausea (45%), vomiting (19%), diarrhea (15%), constipation (16%)—especially at higher doses (>4 mg) and during escalation periods The Peptide Report

• Mild increase in heart rate: dose-dependent, peaking ~24 weeks then declining Alpha Rejuvenation+15New England Journal of Medicine+15PMC+15

• Risks include dehydration, electrolyte imbalance, gallbladder issues, rapid weight loss complications, rare pancreatitis—requires clinical oversight pep-pedia.org.

❓ FAQs

Q: Is Retatrutide FDA‑ or MHRA‑approved?
A: No—it is currently in Phase III trials and is not yet approved for clinical or consumer use. Estimated approval timeframe: late 2025–2027 Alpha Rejuvenation.

Q: How fast is the weight loss?
A: Appetite suppression begins within 24–48 hrs; mild weight loss seen in 2–4 weeks (up to 5–8%), and sustained, dose-related weight loss reaching up to 20–24% by 48 weeks pep-pedia.org.

Q: Who are suitable candidates?
A: Adults with BMI ≥ 30, or ≥ 27 with metabolic comorbidities. Clinical monitoring, labs, and titration protocols are essential.

Q: Can dosage be split?
A: Yes—for lower doses, some users split the weekly dose (e.g. 1 mg twice weekly) following strict reconstitution guidance PMCPeptide Research+4Peptide Research+4Reddit+4.